VCP
ALXN

Verus Capital Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Verus Capital Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$59K Buy
660
+560
+560% +$55K 0.02% 447
2019
Q4 		$11K Buy
+100
New +$10.7K ﹤0.01% 1104

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Verus Capital Partners's ALXN Position: Q1 2020 in Review

Verus Capital Partners increased its Alexion Pharmaceuticals (ALXN) stake by 560% in Q1 2020, buying an estimated $55K and bringing the position to 660 shares worth $59K. The position accounts for 0.02% of the portfolio, ranked #447.

Verus Capital Partners first reported a position in ALXN in Q4 2019 and has held it in 2 quarters since. 653 funds tracked by Wall St. Rank hold ALXN as of Q1 2020.

  • Verus Capital Partners held 660 shares of Alexion Pharmaceuticals worth $59K as of Q1 2020.
  • Verus Capital Partners bought 560 Alexion Pharmaceuticals shares in Q1 2020, an estimated $55K.
  • Alexion Pharmaceuticals made up 0.02% of Verus Capital Partners's portfolio in Q1 2020, its #447 holding.
  • Verus Capital Partners first reported a position in Alexion Pharmaceuticals in Q4 2019 and has held it in 2 quarters since.
  • 653 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2020.

Based on Verus Capital Partners's 13F filing for Q1 2020, filed 26 May 2020.